Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, Chugai) and Rani Therapeutics, LLC, a subsidiary of Rani Therapeutics Holdings, Inc. (Nasdaq: RANI, Rani), a biotherapeutics company focused on the oral delivery of biologics and drugs, announced that they have entered into a Collaboration and License Agreement for the development and commercialization of an oral product consisting of Rani’s oral delivery technology, the RaniPill®, and Chugai’s rare disease antibody in development.
Latham & Watkins, LLP is advising Chugai in the transaction with a corporate deal team led by San Diego/Bay Area partner Chris Hazuka and San Diego counsel Darryl Steensma, with associates Mizuna Sekine and Patrick Chew. Advice was also provided on finance matters by Los Angeles partner Ted Dillman; on securities matters by Bay Area partner Kathleen Wells; and on tax matters by Bay Area partner Kirt Switzer, with associate Derek Gumm.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
